BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Corman S, Elbasha EH, Michalopoulos SN, Nwankwo C. Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection. Value in Health 2017;20:1110-20. [DOI: 10.1016/j.jval.2017.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Guo M, Ke L, You R. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review. Front Public Health 2022;10:836986. [DOI: 10.3389/fpubh.2022.836986] [Reference Citation Analysis]
2 Nguyen J, Barritt AS 4th, Jhaveri R. Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection. J Pediatr. 2019;207:90-96. [PMID: 30738661 DOI: 10.1016/j.jpeds.2018.12.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
3 Yun H, Zhao G, Sun X, Shi L. Cost-utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China. BMJ Open 2020;10:e035224. [PMID: 32819983 DOI: 10.1136/bmjopen-2019-035224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
4 Fawsitt CG, Vickerman P, Cooke G, Welton NJ; STOP-HCV Consortium. A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value Health 2019;22:693-703. [PMID: 31198187 DOI: 10.1016/j.jval.2018.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Yuen MF, Liu SH, Seto WK, Mak LY, Corman SL, Hsu DC, Lee MYK, Khan TK, Puenpatom A. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong. Dig Dis Sci 2021;66:1315-26. [PMID: 32385703 DOI: 10.1007/s10620-020-06281-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Rolli FR, Ruggeri M, Kheiraoui F, Drago C, Basile M, Favaretti C, Cicchetti A. Economic evaluation of Zepatier for the management of HCV in the Italian scenario. Eur J Health Econ 2018;19:1365-74. [PMID: 29696459 DOI: 10.1007/s10198-018-0980-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Miuma S, Miyaaki H, Soyama A, Hidaka M, Takatsuki M, Shibata H, Taura N, Eguchi S, Nakao K. Utilization and efficacy of elbasvir/grazoprevir for treating hepatitis C virus infection after liver transplantation. Hepatol Res 2018;48:1045-54. [PMID: 29908044 DOI: 10.1111/hepr.13204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
8 Espinosa C, Jhaveri R, Barritt AS 4th. Unique Challenges of Hepatitis C in Infants, Children, and Adolescents. Clin Ther 2018;40:1299-307. [PMID: 30107999 DOI: 10.1016/j.clinthera.2018.07.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
9 Suenaga R, Suka M, Hirao T, Hidaka I, Sakaida I, Ishida H. Cost-effectiveness of a "treat-all" strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLoS One 2021;16:e0248748. [PMID: 33793594 DOI: 10.1371/journal.pone.0248748] [Reference Citation Analysis]
10 Goudarzi Z, Poursamad A, Karimzadeh I, Jallaly N, Keshavarz K, Alavian SM. Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C. Hepat Mon 2021;21. [DOI: 10.5812/hepatmon118646] [Reference Citation Analysis]
11 Chugh Y, Dhiman RK, Premkumar M, Prinja S, Singh Grover G, Bahuguna P. Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India. PLoS One 2019;14:e0221769. [PMID: 31465503 DOI: 10.1371/journal.pone.0221769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]